Aktuellt
SENASTE
Redeye revisits the Egetis Therapeutics’ equity story as the company approaches critical clinical milestones. Thanks to new data confirming the long-term efficacy of Emcitate, we see a high likelihood of the flagship project becoming the first market-approved treatment for MCT8 deficiency. With both this and Aladote in the final stages of clinical development, and multiple inflection points ahead, we see compelling short- and long-term potential in the Egetis stock.
LÄS MER
